ORIC Pharmaceuticals Announces Agreement With Cancer Research UK To Advance Potential CIP2A-Targeted Therapy Into Clinical Development
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript